# Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

> **NCT07291102** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 96 (estimated)

## Conditions studied

- Medulloblastoma

## Interventions

- **DRUG:** Bridging Chemotherapy
- **DRUG:** Induction Cycles A1-A3
- **DRUG:** Induction Cycles A4-5
- **DRUG:** Consolidation Cycle A6
- **DRUG:** HIT-SKK Chemotherapy Cycles B1-3
- **DRUG:** Modified HIT-SKK Cycle B4-5

## Key facts

- **NCT ID:** NCT07291102
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2034-10
- **Final completion:** 2038-10
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07291102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07291102, "Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07291102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*